

1
2
3
4 **FIGURE LEGENDS:**
5

6
7 **Figure 1S: Relative abundance of transcripts encoding enzymes involved in lipid**
8 **synthesis in HepG2 and LnCap cells.** Quantitative RT-PCR was used to quantify expression
9 levels of transcripts encoding enzymes involved in lipid metabolism. Primers used for qRT-PCR
10 are listed in Table 1. Results are expressed as mRNA Abundance; Transcript/Cyclophilin. The
11 average C_t value for cyclophilin in HepG2 and LnCap cells was 20.3 ± 0.5 and 19.7 ± 0.3 ,
12 respectively. Results are the mean \pm S.D. three independent samples.
13
14
15
16
17
18
19
20
21
22

23 **Figure 2S: Effect of Soraphen A and C75 on [2- 14 C]-acetate metabolism in HepG2 cells.**

24 HepG2 cells grown to ~80% confluence in DMEM + 10% FBS were treated with DMSO,
25 soraphen A (0.1 -1 μ M) or C75 (50-200 μ M) for 6 hours while cells received [2- 14 C]-acetate (0.5
26 μ Ci/well, 6-well plate). After treatment, cells were harvested & extracted for total lipid (Materials
27 & Methods). Total lipid was fractionated by thin layer chromatography & the distribution of 14 C in
28 lipid fractions was quantified by phosphor image analysis. Lipid standards (cholesterol ester
29 [18:1,n-9], triacylglycerol, [TAG, triolean], non-esterified fatty acids, [NEFA, 18:1,n-9],
30 cholesterol, diacylglycerol [DAG, diolean] and polar lipid [phosphatidyl choline] were obtained
31 from Nu-Chek Prep & Avanti Polar Lipids. Results are expressed as phosphor image
32 units $\times 10^{-5}$ mean \pm S.D., n=3.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Figure 3S: Effect of soraphen A and C75 on fatty acid synthesis, elongation and**
50 **desaturation.**

51
52 **Panel A:** 14 C-labeled lipids from Fig. 1S were saponified and quantified by RP-HPLC & β -
53 scintillation counting. 14 C was recovered in the following fatty acids: myristate (14:0),
54 palmitoleate (16:1,n-7), palmitate (16:0), vaccenate (18:1,n-7) & oleate (18:1,n-9), stearate
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 (18:0). Results are reported as counts per second, CPS, mean \pm SD, n=4.
5

6 **Panel B. Desaturation & Elongation Index.** The desaturation index was calculated by summing
7 the ^{14}C -CPS in [16:1,n-7 + 18:1,n-7 + 18:n-9] & dividing by the sum of ^{14}C -CPS in [14:0 + 16:0
8 + 18:0]. The elongation index was calculated by summing the ^{14}C -CPS in [18:0 + 18:1,n-7 +
9 18:1,n-9] & dividing by the sum of ^{14}C -CPS in [16:0 + 16:1,n-7]. Mean \pm SD, n=4; *, P<0.05
10 versus DMSO.
11
12
13
14
15
16
17
18
19
20

21 **Figure 4S. Effect of elevated FADS1 and FADS2 expression on [1- ^{14}C]-18:2,n-6**

22 **metabolism in HepG2 cells.** HepG2 cells were infected with Ad-Luc, Ad-FADS1, Ad-FADS2 or
23 Ad-FADS1 + Ad-FADS2 at 20 PFU/cell 48 hrs before fatty acid treatment. Cells were treated
24 with 50 μM ^{14}C -linoleate for 6 hrs. Cells were harvested for total lipid extraction and
25 saponification for RP-HPLC fractionation and quantitation of ^{14}C -linoleate elongation &
26 desaturation products. Results are reported as % Distribution of ^{14}C in fatty acids; mean \pm range
27 of 2 separate studies. *. P<0.05 Ad-Luc vs Ad-FADS2 or Ad-FADS1 & 2, ANOVA.
28
29
30
31
32
33
34
35
36
37
38
39

40 **Figure 5S: Effect of elevated elongase activity on *de novo* lipogenesis.** HepG2 cells at
41 ~80% confluence were infected with recombinant adenovirus expressing luciferase (Ad-Luc),
42 fatty acid elongase-5 (Ad-Elovl5) or fatty acid elongase-6 (Ad-Elovl6) at 20 PFU/cell for 48 hrs
43 before metabolic labeling with ^{14}C -acetate. An adenovirus expressing green fluorescent protein
44 (Ad-GFP) was used to establish that at 20 PFU/cells, >90% of these cells express GFP. Cells
45 were treated with [2- ^{14}C]-acetate in the presence of DMSO. Six hours after [2- ^{14}C]-acetate
46 addition, lipids were extracted and fractionated by TLC. The distribution of ^{14}C into polar lipids,
47 diacylglycerol (DAG), cholesterol, non-esterified fatty acids (NEFA), triacylglycerol (TAG) and
48 cholesterol esters (Chol Est) derived from DMSO treated cells.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 **Figure 6S: Soraphen A, but not elevated Elovl5 or Elovl6 expression, increases fatty acid**
8 **oxidation in HepG2 cells.** HepG2 cells were treated with 50 μM [$1\text{-}^{14}\text{C}$]-palmitate [**Panels A**] or
9 [$1\text{-}^{14}\text{C}$]-linoleate [**Panels B**] and DMSO or soraphen A (1 μM). After 6 hrs of treatment, media
10 was collected for analysis of fatty acid oxidation products (Methods). Fatty acid oxidation results
11 are expressed as: nmoles CO_2 . Results are reported as mean \pm SD, n=4, *. $P < 0.05$ vs DMSO,
12
13
14
15
16
17
18
19 t-test.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65